Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Al-Farsi, 2014, Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line, Front Oncol, 4, 157, 10.3389/fonc.2014.00157 Zou, 2008, Inhibitory B7-family molecules in the tumour microenvironment, Nat Rev Immunol, 8, 467, 10.1038/nri2326 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Chen, 2012, Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1, Clin Cancer Res, 18, 6580, 10.1158/1078-0432.CCR-12-1362 Borghaei, 2015, Nivolumab vs. docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab vs. docetaxel in advanced squamous-cell non–small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Herbst, 2015, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Yang, 2011, The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo, J Immunol, 187, 1113, 10.4049/jimmunol.1100056 Butte, 2007, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, 27, 111, 10.1016/j.immuni.2007.05.016 Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330 Akbari, 2010, PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions, Mucosal Immunol, 3, 81, 10.1038/mi.2009.112 Brown, 2003, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production, J Immunol, 170, 1257, 10.4049/jimmunol.170.3.1257 Matsumoto, 2008, B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma, Biochem Biophys Res Commun, 365, 170, 10.1016/j.bbrc.2007.10.156 Spigel, 2015, Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC), J Clin Oncol, 33 Horn, 2015, Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study, J Clin Oncol, 33 Boyd, 2016, Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab, Cancer Immunol Res, 4 Rooney, 2015, Molecular and genetic properties of tumors associated with local immune cytolytic activity, Cell, 160, 48, 10.1016/j.cell.2014.12.033 Johnson, 2003, Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice, Proc Natl Acad Sci USA, 100, 2657, 10.1073/pnas.0538056100 Pearce, 2003, Control of effector CD8+ T cell function by the transcription factor Eomesodermin, Science, 302, 1041, 10.1126/science.1090148 Szabo, 2000, A novel transcription factor, T-bet, directs Th1 lineage commitment, Cell, 100, 655, 10.1016/S0092-8674(00)80702-3 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Ramlau, 2012, Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial, J Clin Oncol, 30, 3640, 10.1200/JCO.2012.42.6932 Paesmans, 1995, Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party, J Clin Oncol, 13, 1221, 10.1200/JCO.1995.13.5.1221 Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 28, 127ra37 Kohrt, 2013, Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1, J Immunother Cancer, 1